Abstract

Genetic insights into the pathophysiology of amyotrophic lateral sclerosis (ALS) are untangling the clinical heterogeneity that may contribute to poor clinical trial outcomes and thus to a lack of effective treatments. Mutations in a large number of genes, including SOD1, C9ORF72, TARDBP, FUS, VAPB, VCP, UBQLN2, ALS2, SETX, OPTN, ANG, and SPG11, are thought to cause ALS, whereas others, including ATAXN2, GRN, HFE, NEFH, UNC13A, and VEGF, appear to be disease-modifying genes. Epigenetic influences may also play important roles. An improved understanding of ALS genetics should lead to better trial designs, insights into common molecular pathways, and better characterization of preclinical models. New genetic sequencing techniques, which use high-throughput methods to assess variants across the genome or exome, may facilitate rational patient stratification for clinical trials and permit more individualized prognostic information and treatment decisions in clinical care.

Original languageEnglish (US)
Pages (from-to)786-803
Number of pages18
JournalMuscle and Nerve
Volume49
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Genetic Heterogeneity
Amyotrophic Lateral Sclerosis
Research
Clinical Trials
Exome
Genetic Techniques
Epigenomics
Vascular Endothelial Growth Factor A
Genes
Genome
Mutation
Therapeutics

All Science Journal Classification (ASJC) codes

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

@article{465f4ebc1e704a3f86c6eb164fb1f7f5,
title = "Genetic heterogeneity of amyotrophic lateral sclerosis: Implications for clinical practice and research",
abstract = "Genetic insights into the pathophysiology of amyotrophic lateral sclerosis (ALS) are untangling the clinical heterogeneity that may contribute to poor clinical trial outcomes and thus to a lack of effective treatments. Mutations in a large number of genes, including SOD1, C9ORF72, TARDBP, FUS, VAPB, VCP, UBQLN2, ALS2, SETX, OPTN, ANG, and SPG11, are thought to cause ALS, whereas others, including ATAXN2, GRN, HFE, NEFH, UNC13A, and VEGF, appear to be disease-modifying genes. Epigenetic influences may also play important roles. An improved understanding of ALS genetics should lead to better trial designs, insights into common molecular pathways, and better characterization of preclinical models. New genetic sequencing techniques, which use high-throughput methods to assess variants across the genome or exome, may facilitate rational patient stratification for clinical trials and permit more individualized prognostic information and treatment decisions in clinical care.",
author = "Su, {Xiaowei W.} and James Broach and James Connor and Gerhard, {Glenn S.} and Zachary Simmons",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/mus.24198",
language = "English (US)",
volume = "49",
pages = "786--803",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

Genetic heterogeneity of amyotrophic lateral sclerosis : Implications for clinical practice and research. / Su, Xiaowei W.; Broach, James; Connor, James; Gerhard, Glenn S.; Simmons, Zachary.

In: Muscle and Nerve, Vol. 49, No. 6, 01.01.2014, p. 786-803.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Genetic heterogeneity of amyotrophic lateral sclerosis

T2 - Implications for clinical practice and research

AU - Su, Xiaowei W.

AU - Broach, James

AU - Connor, James

AU - Gerhard, Glenn S.

AU - Simmons, Zachary

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Genetic insights into the pathophysiology of amyotrophic lateral sclerosis (ALS) are untangling the clinical heterogeneity that may contribute to poor clinical trial outcomes and thus to a lack of effective treatments. Mutations in a large number of genes, including SOD1, C9ORF72, TARDBP, FUS, VAPB, VCP, UBQLN2, ALS2, SETX, OPTN, ANG, and SPG11, are thought to cause ALS, whereas others, including ATAXN2, GRN, HFE, NEFH, UNC13A, and VEGF, appear to be disease-modifying genes. Epigenetic influences may also play important roles. An improved understanding of ALS genetics should lead to better trial designs, insights into common molecular pathways, and better characterization of preclinical models. New genetic sequencing techniques, which use high-throughput methods to assess variants across the genome or exome, may facilitate rational patient stratification for clinical trials and permit more individualized prognostic information and treatment decisions in clinical care.

AB - Genetic insights into the pathophysiology of amyotrophic lateral sclerosis (ALS) are untangling the clinical heterogeneity that may contribute to poor clinical trial outcomes and thus to a lack of effective treatments. Mutations in a large number of genes, including SOD1, C9ORF72, TARDBP, FUS, VAPB, VCP, UBQLN2, ALS2, SETX, OPTN, ANG, and SPG11, are thought to cause ALS, whereas others, including ATAXN2, GRN, HFE, NEFH, UNC13A, and VEGF, appear to be disease-modifying genes. Epigenetic influences may also play important roles. An improved understanding of ALS genetics should lead to better trial designs, insights into common molecular pathways, and better characterization of preclinical models. New genetic sequencing techniques, which use high-throughput methods to assess variants across the genome or exome, may facilitate rational patient stratification for clinical trials and permit more individualized prognostic information and treatment decisions in clinical care.

UR - http://www.scopus.com/inward/record.url?scp=84900832142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900832142&partnerID=8YFLogxK

U2 - 10.1002/mus.24198

DO - 10.1002/mus.24198

M3 - Article

C2 - 24488689

AN - SCOPUS:84900832142

VL - 49

SP - 786

EP - 803

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 6

ER -